INNA SOMINSKY M.D.
Prescription History 1649463522
Internal Medicine - Hematology & Oncology in Brooklyn, NY
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for INNA SOMINSKY M.D., an active Hematology & Oncology specialist practicing in Brooklyn, NY. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 135 documented patient claims. Among these therapy options, the most frequently utilized medication is Hydroxyurea, which accounts for 26 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2024)Rx (2024) | Avg Cost per FillCost / Fill | Vs. Other NY PrescribersVs. NY Avg |
|---|---|---|---|
| Hydroxyurea | 26 | $20.07▼ below NY avg | ▼ Less than typical |
About Hydroxyurea: This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Show more ▾ Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas). An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. In 2024, this provider wrote 26 Medicare prescriptions for Hydroxyurea, about 72% of the volume of the typical New York prescriber of this medication (35.9). Medicare paid an average of $20.07 per fill, versus $21.65 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 38 30-Day Fills standardized to 30-day supplies 1,140 Days of Medication total across all patients in 2024 | |||
| Imatinib Mesylate | 19 | $3,751.82 | ≈ Typical |
About Imatinib Mesylate: This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). Show more ▾ It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome). A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. In 2024, this provider wrote 19 Medicare prescriptions for Imatinib Mesylate, about 86% of the volume of the typical New York prescriber of this medication (22.2). Medicare paid an average of $3,751.82 per fill, versus $1,831.13 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 19 30-Day Fills standardized to 30-day supplies 570 Days of Medication total across all patients in 2024 | |||
| PomalystPomalidomide | 19 | $11,529.11▼ below NY avg | ▼ Less than typical |
About Pomalyst: Pomalidomide is used to treat certain types of cancers (such as multiple myeloma, Kaposi sarcoma). Show more ▾ It works by slowing or stopping the growth of cancer cells. An immunomodulator with antineoplastic and angiogenesis inhibitor activity. In 2024, this provider wrote 19 Medicare prescriptions for Pomalyst, about 65% of the volume of the typical New York prescriber of this medication (29). Medicare paid an average of $11,529.11 per fill, versus $21,304.36 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 19 30-Day Fills standardized to 30-day supplies 532 Days of Medication total across all patients in 2024 | |||
| Lenalidomide | 18 | $12,348.17▼ below NY avg | ▼ Less than typical |
About Lenalidomide: Lenalidomide is used to treat various types of cancers. Show more ▾ It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication. A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA. In 2024, this provider wrote 18 Medicare prescriptions for Lenalidomide, about half the volume of the typical New York prescriber of this medication (37.8). Medicare paid an average of $12,348.17 per fill, versus $13,642.21 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 18 30-Day Fills standardized to 30-day supplies 504 Days of Medication total across all patients in 2024 | |||
| JakafiRuxolitinib Phosphate | 17 | $16,929.47 | ▼ Less than typical |
About Jakafi: This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). Show more ▾ It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system). In 2024, this provider wrote 17 Medicare prescriptions for Jakafi, about half the volume of the typical New York prescriber of this medication (28.9). Medicare paid an average of $16,929.47 per fill, versus $16,282.09 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 17 30-Day Fills standardized to 30-day supplies 510 Days of Medication total across all patients in 2024 | |||
| Allopurinol | 12 | $3.77▼ below NY avg | ▼ Less than typical |
About Allopurinol: Allopurinol is used to treat gout and certain types of kidney stones. Show more ▾ It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems. A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms. In 2024, this provider wrote 12 Medicare prescriptions for Allopurinol, about a quarter of the volume of the typical New York prescriber of this medication (45.6). Medicare paid an average of $3.77 per fill, versus $10.29 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 12 30-Day Fills standardized to 30-day supplies 360 Days of Medication total across all patients in 2024 | |||
| CalquenceAcalabrutinib Maleate | 12 | $13,591.56▼ below NY avg | ▼ Less than typical |
About Calquence: This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Show more ▾ Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors. Inhibits Bruton’s tyrosine kinase; has antineoplastic activity. In 2024, this provider wrote 12 Medicare prescriptions for Calquence, about half the volume of the typical New York prescriber of this medication (28.0). Medicare paid an average of $13,591.56 per fill, versus $14,010.64 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 12 30-Day Fills standardized to 30-day supplies 360 Days of Medication total across all patients in 2024 | |||
| PromactaEltrombopag Olamine | 12 | $12,213.19▼ below NY avg | ▼ Less than typical |
About Promacta: This medication is used to treat low platelet levels in people who have a certain blood disorder called chronic immune (idiopathic) thrombocytopenia purpura (ITP) or who have chronic hepatitis C. Show more ▾ It may also be used to treat people with a certain blood disorder (aplastic anemia). Platelets are a type of blood cell needed to form blood clots and prevent bleeding. Eltrombopag decreases your risk of bleeding by increasing the number of platelets. Eltrombopag acts like a certain natural substance (thrombopoietin) that causes the body to produce platelets. An oral, nonpeptide thrombopoietin receptor agonist. In 2024, this provider wrote 12 Medicare prescriptions for Promacta, about 63% of the volume of the typical New York prescriber of this medication (19). Medicare paid an average of $12,213.19 per fill, versus $13,059.99 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 12 30-Day Fills standardized to 30-day supplies 360 Days of Medication total across all patients in 2024 | |||
About this data. The prescription history for INNA SOMINSKY M.D. is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Hematology & Oncology prescribing approach at this Brooklyn, NY practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among NY prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.
About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.
